《2016年在研精神病药物》.pdfVIP

2 0 1 2 Medicines in Development R e p o Mental Illnesses R t presented by america ’s biopharmaceutical research companies Pharmaceutical Research Companies Are Developing Nearly 200 Medicines to Treat Mental Illnesses and Addictive Disorders ADDICTIVE DISORDERS ANXIETY DISORDERS ATTENTION-DEFICIT/HYPERACTIVITY DISORDERER DEPRESSION DEVELOPMENTAL DISORDERS EATING DISORDERS Medicines in Development SCHIZOPHRENIA PERSONALITY DISORDERS SSLEEEP DISORDERS For Selected Mental Illnesses And Addictive Disorders 1 in 4 American adults suffer from a 52 diagnosable mental illness America’s biopharmaceutical research com- annually in lost wages, health care expendi- panies are developing 187 medicines to help tures, and disability benefits. 36 the nearly 60 million American adults now suf- Examples of some medicines now being fering from some form of mental illness—from tested to treat mental illnesses include: anxiety to depression and from schizophrenia to addictive disorders, such as dependence ? A medicine to potentially treat the various on alcohol or drugs. All of the medicines are symptoms associated with schizophrenia, 26 26 either in clinical trials or awaiting review by with diminished side effects. the Food and Drug Administration. Over the ? An intranasal medicine for the treatment past half century, biopharmaceutical research of anxiety which has shown to improve has helped transform mental illnesses from symptoms within several minutes of misunderstood causes of shame and fear into administration. often highly treatable conditions. For example, Researching and developing new medicines medicines for treating depression are helping remains a risky investment and lengthy thousands of people live productive lives and process. But advances in our understanding breakthrough schizophrenia medicines have of mental illnesses and how to treat them have enabled patients to be treated in the commu- allowed America’s biopharmaceutical com- nity rather than